
Chromatin binding and a permissive epigenetic environment control androgen receptor (AR)-regulated gene expression. A study published in Nature Communications identified high heterogeneity of AR binding sites (ARBS) among primary prostate cancer tumors. ARBS associated with biochemical recurrence were selectively found in metastatic disease samples and were uncommon in the patient population. Copy number alterations acquired during prostate cancer progression affected ARBS that regulate clinically relevant genes and might functionally contribute to cancer phenotypes. In the future, epigenetic heterogeneity might be relevant for personalized medicine in prostate cancer.
Like
Save
Share